secwatch / observer
8-K filed March 16, 2023, 7:59 PM ET ticker CLYM CIK 0001768446
leadership confidence high sentiment neutral materiality 0.60

Eliem Therapeutics Announces CFO Resignation and Appoints New Principal Financial and Accounting Officers

Climb Bio, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Levin

principal financial officer
CLYM · Climb Bio, Inc.
Effective
2023-03-10
Filed
March 16, 2023, 7:59 PM ET
Effective as of March 10, 2023 (the “Transition Date”), the Board appointed (i) Andrew Levin, Executive Chairman, as the Company’s new principal financial officer (in addition to principal executive officer)
Appointed

Emily Pimblett

principal accounting officer
CLYM · Climb Bio, Inc.
Effective
2023-03-10
Filed
March 16, 2023, 7:59 PM ET
and (ii) Emily Pimblett, Chief Accounting Officer, as the Company’s principal accounting officer.
Departed

Erin Lavelle

Executive Vice President, Chief Operating Officer and Chief Financial Officer
CLYM · Climb Bio, Inc.
Effective
2023-03-10
Successor
Andrew Levin
Filed
March 16, 2023, 7:59 PM ET
the Company and Erin Lavelle mutually agreed that Ms. Lavelle would resign as Executive Vice President, Chief Operating Officer and Chief Financial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Levin was appointed as principal financial officer at Climb Bio, Inc..

Action
appointed
Role
principal financial officer
Exact text from the filing
Effective as of March 10, 2023 (the “Transition Date”), the Board appointed (i) Andrew Levin, Executive Chairman, as the Company’s new principal financial officer (in addition to principal executive officer)
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Emily Pimblett was appointed as principal accounting officer at Climb Bio, Inc..

Action
appointed
Role
principal accounting officer
Exact text from the filing
and (ii) Emily Pimblett, Chief Accounting Officer, as the Company’s principal accounting officer.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Erin Lavelle resigned as Executive Vice President, Chief Operating Officer and Chief Financial Officer at Climb Bio, Inc..

Action
resigned
Role
Executive Vice President, Chief Operating Officer and Chief Financial Officer
Exact text from the filing
the Company and Erin Lavelle mutually agreed that Ms. Lavelle would resign as Executive Vice President, Chief Operating Officer and Chief Financial Officer of the Company.
View on SEC.gov

Climb Bio, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-072646
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.